RVXCF (Resverlogix) Price-to-Tangible-Book : (As of May. 12, 2025)

View and export this data going back to 2010. Start your Free Trial

What is Resverlogix Price-to-Tangible-Book?

As of today (2025-05-12), Resverlogix's share price is $0.025. Resverlogix's Tangible Book per Share of Dec. 2024 for the quarter that ended in Dec. 2024 was $-0.30. Hence, Resverlogix's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for Resverlogix's Price-to-Tangible-Book or its related term are showing as below:

RVXCF's Price-to-Tangible-Book is not ranked ^*
in the Biotechnology industry.
Industry Median: 2.61
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Resverlogix's share price is $0.025. Resverlogix's Book Value per Sharefor the quarter that ended in Dec. 2024 was $-0.29. Hence, Resverlogix's P/B Ratio of today is .

Resverlogix Price-to-Tangible-Book Historical Data

The historical data trend for Resverlogix's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Resverlogix Price-to-Tangible-Book Chart

Resverlogix Annual Data

Trend

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Dec21

Dec22

Dec23

Dec24

Price-to-Tangible-Book

Get a 7-Day Free Trial

Resverlogix Quarterly Data
	Jan20	Apr20	Jul20	Oct20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Price-to-Tangible-Book	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Resverlogix's Price-to-Tangible-Book

For the Biotechnology subindustry, Resverlogix's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Resverlogix's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Resverlogix's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Resverlogix's Price-to-Tangible-Book falls into.

Save Embed

;

Save Embed

;

Resverlogix Price-to-Tangible-Book Calculation

Resverlogix's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2024 )
	=	0.025	/	-0.3
	=

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Resverlogix Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Resverlogix's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Resverlogix Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Resverlogix Corp (OTCPK:RVXCF) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

RVX:Canada

Address

4820 Richard Road South West, Suite 300, Calgary, AB, CAN, T3E 6L1

Website

https://www.resverlogix.com

Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.